Imexpharm (STC:IMP) ROE % Adjusted to Book Value: 3.96% (As of Mar. 2026)


STC:IMP Imexpharm Corp STC:IMP
98 GF Score
Price ₫42,900.00
GF Value ₫51,706.57
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Imexpharm ROE % Adjusted to Book Value?

Imexpharm STC:IMP 98 ROE % Adjusted to Book Value is 3.96% as of Mar. 2026. GuruFocus rates STC:IMP with a GF Score™ of 98/100 and a GF Value™ of ₫51,706.57 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Imexpharm's ROE % for the quarter that ended in Mar. 2026 was 14.01%. Imexpharm's PB Ratio for the quarter that ended in Mar. 2026 was 3.54. Imexpharm's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 3.96%.

Imexpharm ROE % Adjusted to Book Value Related Terms

Imexpharm ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Imexpharm's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imexpharm ROE % Adjusted to Book Value Chart

Imexpharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.71 5.72 7.93 4.53 4.43

Imexpharm Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.41 4.43 3.86 5.44 3.96

STC:IMP vs ZTS: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Imexpharm's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Imexpharm ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Imexpharm's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Imexpharm's ROE % Adjusted to Book Value falls into.


STC:IMP
98GF Score
Imexpharm Corp STC:IMP
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imexpharm ROE % Adjusted to Book Value Calculation

Imexpharm's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=15.55% / 3.51
=4.43%

Imexpharm's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=14.01% / 3.54
=3.96%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 3.96% mean?
Imexpharm (STC:IMP) has a ROE % Adjusted to Book Value of 3.96% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Imexpharm and its competitors.
Is Imexpharm's ROE % Adjusted to Book Value too high?
Imexpharm's current ROE % Adjusted to Book Value is 3.96%. Overall, Imexpharm has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Imexpharm's ROE % Adjusted to Book Value compare to ZTS?
Imexpharm's ROE % Adjusted to Book Value of 3.96% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Imexpharm and its competitors. Imexpharm's current ROE % Adjusted to Book Value is 3.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imexpharm stock overvalued right now?
Based on GuruFocus' analysis, Imexpharm (STC:IMP) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫51,706.57, compared to a current price of ₫42,900.00 — trading 17% below its estimated fair value. The current ROE % Adjusted to Book Value is 3.96%. Imexpharm's overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Imexpharm (STC:IMP), the current ROE % Adjusted to Book Value is 3.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Imexpharm (STC:IMP) Overvalued in 2026?

Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued. The current stock price of ₫42,900.00 is trading 17% below its estimated GF Value™ of ₫51,706.57. GuruFocus considers Imexpharm to be Modestly Undervalued.

Key valuation signals for STC:IMP:

  • ROE % Adjusted to Book Value: 3.96%
  • GF Value™: ₫51,706.57 vs. price of ₫42,900.00 (17% below fair value)
  • GF Score™: 98/100 with 2 warning signs

No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Imexpharm Business Description

Address 4 Road 30/04 Street Ward 1, Cao Lanh City, Dongthap, VNM
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
98GF Score

Get the complete analysis for STC:IMP

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫42,900.00
Price
₫51,706.57
GF Value